We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+38.67%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$144M
AUM Growth
+$17.4M
Cap. Flow
-$19.7M
Cap. Flow %
-13.73%
Top 10 Hldgs %
45.16%
Holding
104
New
9
Increased
14
Reduced
21
Closed
29

Top Buys

Rank Stock Value
1
TNDM icon
Tandem Diabetes Care
TNDM
+$3M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.63M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$2.32M
4
ONC
BeOne Medicines Ltd
ONC
+$2.04M
5
ARDX icon
Ardelyx
ARDX
+$1.98M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$4.73M
2
RIGL icon
Rigel Pharmaceuticals
RIGL
+$4.32M
3
NVAX icon
Novavax
NVAX
+$4M
4
DERM
Dermira, Inc.
DERM
+$3.05M
5
NXTM
NxStage Medical Inc.
NXTM
+$2.75M

Sector Composition

Rank Sector Weight
1 Healthcare 68.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSTC
26
DELISTED
BioSpecifics Technologies Corp.
BSTC
$1.81M 1.26%
39,704
– –
CYTK icon
27
Cytokinetics
CYTK
$10.8B
$1.67M 1.16%
181,737
+31,737
+21% +$331K
DSCI
28
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$1.65M 1.15%
353,718
– –
SPNC
29
DELISTED
Spectranetics Corp
SPNC
$1.64M 1.14%
65,496
-14,316
-18% -$334K
MGNX icon
30
MacroGenics
MGNX
$245M
$1.62M 1.13%
54,200
– –
QURE icon
31
uniQure
QURE
$2.52B
$1.56M 1.09%
203,907
+45,000
+28% +$357K
SGYP
32
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.51M 1.05%
274,563
-45,000
-14% -$211K
ACHN
33
DELISTED
Achillion Pharmaceuticals
ACHN
$1.51M 1.05%
186,500
-50,000
-21% -$425K
BEAT
34
DELISTED
BioTelemetry, Inc.
BEAT
$1.49M 1.04%
80,000
-20,000
-20% -$377K
RGLS
35
DELISTED
Regulus Therapeutics
RGLS
$1.39M 0.97%
3,513
– –
RIGL icon
36
Rigel Pharmaceuticals
RIGL
$712M
$1.25M 0.87%
34,000
-150,709
-82% -$4.32M
WINT
37
DELISTED
Windtree Therapeutics Inc
WINT
$1.23M 0.86%
480,833
-52,525
-10% -$114K
EIGR
38
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.21M 0.84%
+3,000
New +$1.53M
STXS icon
39
Stereotaxis
STXS
$128M
$1.19M 0.83%
1,372,862
– –
NVDQ
40
DELISTED
Novadaq Technologies Inc.
NVDQ
$1.18M 0.82%
101,841
– –
JNJ icon
41
Johnson & Johnson
JNJ
$643B
$1.11M 0.77%
9,400
– –
ZGNX
42
DELISTED
Zogenix, Inc.
ZGNX
$909K 0.63%
79,538
-118,000
-60% -$1.09M
EXAC
43
DELISTED
Exactech Inc
EXAC
$855K 0.6%
31,636
– –
SCYX icon
44
SCYNEXIS
SCYX
$36M
$825K 0.57%
2,666
-670
-20% -$141K
EPIX
45
DELISTED
ESSA Pharma
EPIX
$733K 0.51%
9,775
-350
-3% -$18.7K
DRNA
46
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$701K 0.49%
119,300
– –
CNCE
47
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$677K 0.47%
66,968
– –
CGNT
48
DELISTED
Cogentix Medical, Inc.
CGNT
$643K 0.45%
353,482
+600
+0.2% +$776
ASND icon
49
Ascendis Pharma A/S
ASND
$16.7B
$618K 0.43%
30,750
-22,491
-42% -$371K
ELOS
50
DELISTED
Syneron Medical Ltd
ELOS
$615K 0.43%
85,947
– –
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, DAFNA Capital Management held 104 positions worth $144M, up 14% from $126M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

DAFNA Capital Management withdrew a net $19.7M in Q3 2016, closing 29 positions and reducing 21 holdings. Its most notable exit was AbbVie, an estimated $4.73M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 71% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in IVERIC bio, Inc. Common Stock worth $2.15M.

  • DAFNA Capital Management's largest Q3 2016 buy was IVERIC bio, Inc. Common Stock: 46,600 shares worth $2.15M.
  • DAFNA Capital Management added most to Tandem Diabetes Care in Q3 2016, an estimated $3M increase.
  • DAFNA Capital Management's biggest Q3 2016 reduction was Rigel Pharmaceuticals, cutting an estimated $4.32M.
  • DAFNA Capital Management fully exited AbbVie in Q3 2016, selling an estimated $4.73M.
  • DAFNA Capital Management's ten largest holdings make up 45% of its $144M portfolio in Q3 2016.
  • DAFNA Capital Management opened 9 new positions and closed 29 in Q3 2016.
  • DAFNA Capital Management's portfolio value rose 14% quarter-over-quarter to $144M.

Based on DAFNA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.